Hematologic Toxicity Observation of the Docetaxel+ Cisplatin+ Fluorouracil (TPF)Medical Protocol (OTOHTPF)

Groupe Oncologie Radiotherapie Tete et Cou

Status: Completed

Conditions: Squamous Cell Head and Neck Carcinoma

Study type: Observational

Funder types: Other

Identifiers

NCT01268878

GORTEC 2010-01

Details and patient eligibility

About

The ending of this study is to describe the effect of febrile neutropenia on patients who receive a chemotherapy by docetaxel+cisplatin+fluorouracil(TPF).

Full description

In this study we will describe

• habits of medical staff in prescription of growth factors or antibiotic prophylaxis
• ratio of patients treated by growth factors in primary or secondary prophylaxis
• ratio of patients treated in primary prophylaxis who present a febrile neutropenia
• ratio of patients who need to be hospitalized and the duration of those hospitalizations.
• causes of lateness, of decreasing, and of stop of chemotherapy
• antibiotic and growth factors prophylaxis tolerance .

Enrollment: 130 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with histologically proved head and neck squamous cell carcinoma
• age: more than 18
• patients who are beginning a chemotherapy (docetaxel+cisplatin+ 5FU)
• patients must have been informed of automatic data processing concerning them.

Exclusion criteria

• previous chemotherapy for the head and neck squamous cell carcinoma
• previous chemotherapy for an other cancer in the two years before
• intercurrent illness that could significantly interfere with chemotherapy such as HIV infection, infection or active febrile illness, a chronic intestinal disease